These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25160805)

  • 1. Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal follicle-stimulating hormone or lower mature oocytes.
    Kung HF; Chen MJ; Guua HF; Chen YF; Yi YC; Yen-Ping Ho J; Chou MM
    J Chin Med Assoc; 2014 Oct; 77(10):524-30. PubMed ID: 25160805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteal phase support for assisted reproduction cycles.
    van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
    Cochrane Database Syst Rev; 2011 Oct; (10):CD009154. PubMed ID: 21975790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteal phase support with gonadotropin-releasing hormone agonist.
    Tsui KH; Lin LT; Wang PH
    J Chin Med Assoc; 2014 Oct; 77(10):505-7. PubMed ID: 25027751
    [No Abstract]   [Full Text] [Related]  

  • 4. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis].
    Yu LP; Liu N; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):850-858. PubMed ID: 27916070
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis.
    Oliveira JB; Baruffi R; Petersen CG; Mauri AL; Cavagna M; Franco JG
    Reprod Biol Endocrinol; 2010 Sep; 8():107. PubMed ID: 20825643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation].
    Kdous M; Chaker A; Bouyahia M; Zhioua F; Zhioua A
    Tunis Med; 2009 Dec; 87(12):834-42. PubMed ID: 20209851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of modified luteal phase support with intramuscular progesterone in IVF/ICSI cycles: a retrospective observational study.
    Conforti A; Strina I; Mollo A; Amoroso R; Marrone V; Alviggi C; Marci R; de Placido G
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(4):657-661. PubMed ID: 28272720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.
    Aboulghar MA; Marie H; Amin YM; Aboulghar MM; Nasr A; Serour GI; Mansour RT
    Reprod Biomed Online; 2015 Jan; 30(1):52-6. PubMed ID: 25456166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?
    Chen X; Feng SX; Guo PP; He YX; Liu YD; Ye DS; Chen SL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):215-220. PubMed ID: 27072965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Peak Estradiol/Mature Oocyte Ratio Predicts Lower Clinical Pregnancy, Ongoing Pregnancy, and Live Birth Rates in GnRH Antagonist Intracytoplasmic Sperm Injection Cycles.
    Sandoval JS; Steward RG; Chen C; Li YJ; Price TM; Muasher SJ
    J Reprod Med; 2016; 61(1-2):11-6. PubMed ID: 26995882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Gonadotrophin-Releasing Hormone Agonist Addition for Luteal Support on Pregnancy Outcome in vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: A Meta-Analysis Based on Randomized Controlled Trials.
    Ma X; Du W; Hu J; Yang Y; Zhang X
    Gynecol Obstet Invest; 2020; 85(1):13-25. PubMed ID: 31422404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study.
    Ata B; Yakin K; Balaban B; Urman B
    Hum Reprod; 2008 Mar; 23(3):668-73. PubMed ID: 18192671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.
    Razieh DF; Maryam AR; Nasim T
    Taiwan J Obstet Gynecol; 2009 Sep; 48(3):245-8. PubMed ID: 19797013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles.
    Chen H; Wang Y; Lyu Q; Ai A; Fu Y; Tian H; Cai R; Hong Q; Chen Q; Shoham Z; Kuang Y
    Fertil Steril; 2015 May; 103(5):1194-1201.e2. PubMed ID: 25813280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.